Fibroblast proliferation pathways

Fibroblast proliferation pathways represent a complex network of intracellular and extracellular signaling events that govern the growth, activation, and phenotypic transition of fibroblasts into myofibroblasts. Central to these pathways are growth factor signaling systems, most notably the Transforming Growth Factor-beta (TGF-β), Platelet-Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF) families (Source: PubMed, PMC4297108). In a physiological context, these pathways are vital for normal wound healing and the maintenance of connective tissue integrity by regulating the production of extracellular matrix components like collagen and fibronectin (Source: StatPearls, Fibrosis). However, chronic or dysregulated activation of these pathways leads to pathological fibrosis in organs such as the lungs, liver, and kidneys, as well as the formation of a supportive stroma for tumor cells in various cancers (Source: NIH, National Cancer Institute). Pharmacological targeting of these pathways often involves the use of multi-kinase inhibitors, such as Nintedanib, which blocks the ATP-binding sites of PDGFR, FGFR, and VEGFR, thereby inhibiting the downstream signaling required for fibroblast proliferation and migration (Source: FDA, Ofev Prescribing Information). While effective in slowing disease progression in conditions like idiopathic pulmonary fibrosis, these interventions carry risks such as impaired wound healing and gastrointestinal toxicity due to the broad physiological roles of the targeted growth factor receptors (Source: Mayo Clinic).

Other names

Fibroblast activation pathwaysFibrogenesis signalingFibroblast growth pathwaysMyofibroblast differentiation pathways

Inhibition of receptor tyrosine kinases (RTKs) including PDGFR, FGFR, and VEGFR, or modulation of TGF-beta signaling to reduce fibroblast activation and proliferation.